Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians

Affiliations

• ¹ Department of Medicine, University of Washington, Seattle, WA, USA. rahul.banerjee.md@gmail.com.
• ² Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rahul.banerjee.md@gmail.com.
• ³ Willamette Valley Cancer Institute, Eugene, OR, USA.
• ⁴ Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
• ⁵ Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia.
• ⁶ Garvan Institute of Medical Research, University of New South Wales, Sydney, NSW, Australia.
• ⁷ Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, India.
• ⁸ Department of Medicine, University of Washington, Seattle, WA, USA.
• ⁹ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
• ¹⁰ Division of Hematology, Mayo Clinic, Rochester, MN, USA.